- Home
- BGB vs RGNX Comparison
BGB vs RGNX Comparison
Compare BGB & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BGB | RGNX |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 496.4M | 418.1M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | BGB | RGNX |
|---|---|---|
| Price | $11.21 | $8.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $28.75 |
| AVG Volume (30 Days) | 151.9K | ★ 501.7K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 9.75% | N/A |
| EPS Growth | N/A | ★ 18.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,393,000.00 |
| Revenue This Year | N/A | $51.21 |
| Revenue Next Year | N/A | $19.08 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 126.48 |
| 52 Week Low | $10.85 | $6.89 |
| 52 Week High | $12.65 | $16.19 |
Technical Indicators
Market Signals| Indicator | BGB | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 47.45 | 46.91 |
| Support Level | $10.98 | $8.68 |
| Resistance Level | $11.51 | $9.29 |
| Average True Range (ATR) | 0.09 | 0.48 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 40.61 | 28.57 |
Price Performance
Historical ComparisonAbout BGB Blackstone Strategic Credit 2027 Term Fund of Beneficial Interest
Blackstone Strategic Credit Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek high current income. The secondary objective of the fund is to seek the preservation of capital. Under normal market conditions, the Fund invests at least 80% of its Managed Assets in senior, secured floating-rate loans. The fund also invest in second-lien loans and high yield bonds and employs financial leverage, which may increase risk to the Fund. The Fund has a limited term and absent shareholder approval to extend the life of the Fund.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.